(Q36113050)

12 August 2017

1 reference

title

Combination therapy in multiple sclerosis. (English)

1 reference

12 August 2017

Mark J Tullman

1

1 reference

PubMed ID

15865891

12 August 2017

Fred D Lublin

series ordinal

2

1 reference

12 August 2017

1 May 2005

1 reference

Current Neurology and Neuroscience Reports

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

3

1 reference

12 August 2017

245-248

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-005-0053-9

12 August 2017

0 references

cites work

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0053-9

Effect of relapses on development of residual deficit in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0053-9

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0053-9

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0053-9

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0053-9

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0053-9

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-005-0053-9

Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis

21 January 2018

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group

1 reference

12 December 2020

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

1 reference

12 December 2020

Overview of azathioprine treatment in multiple sclerosis

1 reference

12 December 2020

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

12 December 2020

Axonal transection in the lesions of multiple sclerosis

1 reference

12 December 2020

Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.

1 reference

12 December 2020

Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality

1 reference

12 December 2020

10.1007/S11910-005-0053-9

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15865891